Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$1.24 - $2.09 $29,404 - $49,560
23,713 Added 448.68%
28,998 $37,000
Q2 2022

Aug 15, 2022

BUY
$1.99 - $3.85 $10,517 - $20,347
5,285 New
5,285 $11,000

Others Institutions Holding ADAG

About Adagene Inc.


  • Ticker ADAG
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,423,200
  • Market Cap $105M
  • Description
  • Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid ...
More about ADAG
Track This Portfolio

Track Cannell Capital LLC Portfolio

Follow Cannell Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cannell Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cannell Capital LLC with notifications on news.